Tucker, Zachary

From:

Tucker, Zachary

Sent:

Wednesday, December 14, 2005 9:49 AM

To:

STIC-ILL *

Subject:

REFERENCE REQUEST

My name is Zachary Tucker I am in REM 5C04 My phone number is 571-272-0677

I would very much like to have a copy of this article for a case I am working on:

TI Reappraising first-line treatment in glaucoma management.

AU Phelan Peter

CS Sunderland Eye Infirmary, Sunderland SR2 9HP.

SO Hospital medicine (London, England : 1998), (2002 Sep) 63 (9) 540-5. Ref: 42

Journal code: 9803882. ISSN: 1462-3935.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW) (REVIEW, TUTORIAL)

LA English

It is for case serial no. 10/622,055. Thank you very much.

WAITING FOR THIS REFERENCE

Serotonin modifies the neuronal inhibitory responses to gamma-aminobutyric acid in the red nucleus: a microiontophoretic study in the rat. Lidata F; Li Volai G; Di Mauro M; Fretto G; Ciranna L; Santangelo F. Department of Physiological Sciences, University of Catania, Catania, 95125, Italy. Interaction of serotonin and cholecystokinin in the lateral parabrachial nucleus to control sodium inteke.

Fratuczi De Gobbi JI: De Luca L A Jr; Johnson A K; Menani J V
Department of Physiology and Pathology, School of Dentistry, Paulista State University (UNESP), 14801 - 903 Araraquara, Sao Paulo, Brazil.

HL-1388 (NHLBI) American journal of physiology. Regulatory, integrative and comparative physiology, (2001 May) 280 (5) R1301-7. Journal code: 100901230. ISSN: 0363-6119. Pubbed ID: 11277605

Discriminative stimulus properties of indorenate, a 5-HTlA, 5-HTlB and Discriminative stimulus properties of indorenate, a 5-HTlA, 5-HTlB and 5-HTC agonist: a study in rats.

Sanchez H: Velazquez-Martinez D N
Departamento de Paicofisiologia, Facultad de Psicologia, Universidad Nacional Autonoma de Mexico, Mexico DF.

Journal of psychopharmacology (Oxford, England), (2001 Max) 15 School of Medicine, University of Pennsylvania, 19104-4283, USA. Sleep, (2001 Mar 15) 24 (2) 155-60. Journal code: 7809084. ISSN: 0161-8105. Journal code: 8907828. ISSN: 0269-8811. Priority Journals; Space Life Sciences Journal; Article; (JOURNAL ARTICLE) Journal; Article; (JOURNAL ARTICLE) Journal; Article; (JOURNAL ARTICLE) MEDLINE on STN 2 MEDLINE on STN MEDLINE 2 MEDLINE on STN MEDLINE Last Updated on STN: 20011023 Entered Medline: 20010517 Last Updated on STN: 20010730 Entered Medline: 20010726 Last Updated on STN: 20030118 Entered Medline: 20010719 veasey@mail.med.upenn.edu HL-60287 (NHLBI) Entered STN: 20010521 Entered STN: 20010723 Entered STN: 20010730 PubMed ID: 11294747 PubMed ID: 11161597 Priority Journals Priority Journals ANSWER 20 OF 22 ANSWER 21 OF 22 ANSWER 22 OF 22 United States United States United States 2001140842 English English English 200107 200107 CAU TINA BESEDS SK So BEREZE BESEAC

ANSWER IN OF 11321

AND COUNTRY: Medullary thyroid carry germ-line mutathors in REI (rearranged during transfection).

However, most WTC occur in Andividuals without a family history.

BUECTIVES: The Objective of this study was to explore the possibility that susceptibility in these cases results from lub penetrance alleles of RET, its coreceptors, and ligands. DESIGNS We carried out an association Study in 135 sporadic WTC (SMTC) patients and 533 controls from the United Kingdom population. RESULTS AND CONCLUSIONS: We analyzed 3 polymorphisms in all nine genes involved in the gilal cell line-derived neurotropic factor receptor-alpha (GFRalpha)-RET complex. This is the first association study in which all genes involved in this complex have been investigated for susceptibility to SMTC. We did not find any association between single nucleotide polymorphisms in the exonic regions of the GFRalpha, GFRalpha, glial cell line-derived neurotropic actor, neurourin, or persephini genes and risk of developing sMTC. We found a strong association between the disease and specific haplotypes of factor, neurourin, or persephini genes and risk of developing sMTC. We found a strong association between the disease and specific haplotypes of SE2-2.82; P = 0.004), but we found a novel protective effect associated with a specific haplotype (odds ratio, 0.39; range, 1.

P = 0.005) revealing the exatence of different genetic variants in the RET oncogene that either increase or decrease risk of SMTC. code: 0370712. ISSN: 0014-4886. MEDLINE on STN Journal; Article; (JOURNAL ARTICLE) Entered STN: 20010404 Last Updated on STN: 20030118 Entered Medline: 20010308 ANSWER 18 OF 11321 Priority Journals United States Journal English -> D ABS 18 200103 EERSE L6 AB

D L5 ABS 18 ĥ

LS ANSWER 18 OF 22 MEDLINE on STN

AB Irritable bowel syndrome (IES) is a functional gut disorder the diagnosis of which is based on clinical symptoms as set forth by the Rome criteria. As the population ages, especially with the population of patients >75 of the most common diseases of the electry. Thus far, developing one treatment strategies for patients with IBS has been difficult because of the lack of pharmacological targets and the wide range of symptomatology. Additionally, demonstration of a therapeutic benefit is difficult in the presence of a high placebo response observed regardless of the therapy employed. Fibre, antidiarchoeals and antispasmodics all play some robe in the symptomatic treatment of IBS. With the evolution of IBS as a disorder of visceral hypersensitivity, new drugs have been developed that target the enterin nervous system. Tricyclic antidepressants (TCAS) have been found to target the enterin nervons and play a role in pain modulation. The newest class of drugs to be approved for use in IBS are the serotonin (5-hydroxytryptamine; 5-HT) arceptor antagonists have been shown to decrease symptoms in female patients with IBS. A related class of drugs, the 5-HT4 receptor agonists, is being developed for the treatment of constipation-predominant IBS. Further investigation into the role of spinal afferent neurons in visceral hypersensitivity is at the forefront of IBS research. Several experimental drug therapies for IBS are also BE

Experimental neurology, (2001 Jan) 167 (1) 95-107.

ANSWER 2 OF 3 MEDLINE MEDLINE on STN L9

AN

DN PubMed ID: 12357857

Reappraising first-line treatment in glaucoma management. TI

ΑU Phelan Peter

Sunderland Eye Infirmary, Sunderland SR2 9HP. CS

Hospital medicine (London, England: 1998), (2002 Sep) 63 (9). so 540-5. Ref: 42

Journal code: 9803882. ISSN: 1462-3935.

CYEngland: United Kingdom

Journal; Article; (JOURNAL ARTICLE) DTGeneral Review; (REVIEW) (REVIEW, TUTORIAL)

LA English

Priority Journals FS

200212 EM

Entered STN: 20021003 ED

> Last Updated on STN: 20021221 Entered Medline: 20021220

MEDLINE on STN ANSWER 2 OF 3

Despite treatment, glaucoma patients may still suffer vision loss because of inadequate control of intraocular pressure or late presentation. This article reviews the latest evidence supporting a reappraisal of first-line treatment in the management of glaucoma, including a review of latanoprost, recently approved for first-line treatment of glaucoma and ocular hypertension.